Clinical Trial

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab. The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-30; most recent amendment 2026-04-10.
Status change: Not Yet Recruiting → Recruiting 2026-04-10
Trial Details
NCT Number NCT07107529
Lead Sponsor European Myeloma Network B.V.
Collaborators: EMN Trial Office S.r.l. Impresa Sociale, HOVON - Dutch Haemato-Oncology Association, PETHEMA Foundation, Nordic Myeloma Study Group, Janssen Pharmaceutica N.V., Belgium
Conditions Multiple Myeloma (MM)
Enrollment 150 participants
Start Date 2025-12-12
Primary Completion 2029-04 (estimated)
Study Completion 2034-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-15